Compare RFL & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | ZTEK |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 68.8M |
| IPO Year | 2017 | 2022 |
| Metric | RFL | ZTEK |
|---|---|---|
| Price | $1.23 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 63.2K | 47.9K |
| Earning Date | 03-16-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $0.50 |
| 52 Week High | $3.19 | $1.84 |
| Indicator | RFL | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 44.68 | 39.70 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.32 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 14.81 | 29.80 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.